We thus aimed to develop genetic instruments for the targets of five approved type 2 diabetes medications with known mechanisms of action (sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)], PPARG, SGLT2, DPP4 and GLP1R). Here, ABCC8 is linked to type 2 diabetes mellitus.